Symbols / TAK $18.21 +0.77%

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-licensing agreements with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaborations with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Institute, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, and Teva Pharmaceutical Industries; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei, Zedira/Dr. Falk Pharma, Exelixi GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, KM Biologics, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Price estimates from analyst targets and simple models.

Latest analyst rating changes

• The Technical Signals Behind (TAK) That Institutions Follow - Stock Traders Daily ue, 10 Mar 2026 17
• Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026? - Yahoo Finance Sat, 31 Jan 2026 08
• FDA Grants Priority Review for Takeda (TAK) and Protagonist’s Rusfertide in PV Treatment - Insider Monkey Sun, 08 Mar 2026 16
• ENTYVIO trial sees 47% of kids with moderate/severe colitis in remission - Stock Titan hu, 19 Feb 2026 08
• From the ground up: The faces behind APAC’s stock loan market - Securities Finance Times ue, 17 Feb 2026 08
• Takeda's shares fall as it trims full-year guidance, pipeline - FirstWord Pharma hu, 30 Oct 2025 07
• Takeda: Lack Of Realistic Upside In Japanese Pharma (NYSE:TAK) - Seeking Alpha hu, 11 Dec 2025 08
• Takeda Pharmaceutical (NYSE:TAK) Reaches New 12-Month High - Here's What Happened - MarketBeat Wed, 18 Feb 2026 08
• Takeda Pharmaceutical’s Valuation After ENTYVIO Pediatric Data And TAK-861 Priority Review - simplywall.st ue, 24 Feb 2026 08
• FDA grants priority review to new injection for blood disorder polycythemia vera - Stock Titan Mon, 02 Mar 2026 08
• Precision Trading with Takeda Pharmaceutical Company Limited American Depositary Shares (each Representing 1/2 Of A Share Of) (TAK) Risk Zones - Stock Traders Daily Fri, 27 Feb 2026 15
• Takeda: Excellent Pipeline Kaizen - 6 Drugs, $20 Billion Annually (NYSE:TAK) - Seeking Alpha Wed, 24 Sep 2025 07
• Innovent Biologics, Takeda (NYSE: TAK) seal IO, ADC pact worth up to $11.4 billion - Stock Titan hu, 04 Dec 2025 08
• Technical Reactions to TAK Trends in Macro Strategies - Stock Traders Daily Mon, 16 Feb 2026 08
• Once-daily pill from Takeda helps many psoriasis patients reach clear skin - Stock Titan hu, 18 Dec 2025 08

• Income Statement
• Balance Sheet
• Cash Flow

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

• 42025-12-09 View
• 42025-09-19 View
• 42024-01-25 View
• 42023-05-26 View
• 42022-12-01 View
• 42022-07-06 View
• 42022-07-06 View
• 42022-03-16 View
• 42021-12-09 View
• 42021-12-07 View
• 42021-11-29 View
• 42021-11-08 View
• 42021-10-26 View
• 42021-10-15 View
• 42021-07-09 View